Dr Tristan Barber
MA MD (Cantab.) FRCP BSc MB BChir DRCOG DFSRH Dip. HIV Med. Dip GUM
Consultant in HIV Medicine
Dr Barber is a consultant physician and healthcare services professional with expertise spanning HIV and sexual/reproductive health (genitourinary medicine).
He is a national and international leader in the HIV field who drives clinical improvements whilst always championing patient centred and holistic care, collaborative and shared decision making and instilling a culture of exceptional treatment. He is HIV co-lead for a bespoke service focused on HIV, frailty and ageing. Dr Barber is accustomed to gathering, disseminating and leveraging data to streamline and deliver improvements across HIV and sexual and reproductive health.
He was awarded his MD by the University of Cambridge in 2019 for research in HIV-related neurocognitive impairment.
Dr Barber is currently Honorary Secretary for the British HIV Association (BHIVA) and Chair of the BHIVA Education and Scientific Subcommittee, as well as being editor-in-chief for the journal ‘HIV Research and Clinical Practice’.
In his spare time he enjoys cooking, theatre, and year-round open water swimming.
Hospital Locations
Royal Free Hospital
Year qualified
1999
Country of qualification
UK
Languages spoken
English and basic French
Specialities
Genitourinary Medicine
Memberships
- General Medical Council #4582753
- Fellow, Royal College of Physicians #115842
- Diplomate, Royal College of Obstetricians and Gynaecologists
- Diplomate, Faculty of Sexual and Reproductive Healthcare
- Fellow, British Association for Sexual Health and HIV (BASHH) #00473221
- Member, British HIV Association (BHIVA) #23181
- Trustee, BHIVA Executive Committee
- Member, HIV Clinical Reference Group (CRG)
- Member, Steering Committee, EACS Young Investigator Network (YING)
Registration and licensing
GMC:4582753
Procedures offered
Dr Barber is available for all aspects of HIV care and treatment.
Research interests
Dr Barber currently has research projects examining aspects of HIV and ageing, the interaction of HIV on SARS CoV-2 antibody positivity and a planned clinical trial looking at the action of doravirine in patients with known antiretroviral associated resistance mutations. His research background is in HIV vaccine studies, phase three antiretroviral trials and HIV related neurocognitive impairment.